GlassScriptPhysician profile
Veronica P Mcgregor
NPI 1154395614
$6,756.85
in general payments reported to CMS, 2019-2025
45 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $373 · 2021: $1,126 · 2022: $650 · 2023: $887 · 2024: $1,316 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,770 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,770.07 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,271.42 | 2019-2025 | Freestyle Libre 3, Eterna |
| Dexcom, INC. | $724.93 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $619.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $345.29 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Sequel Med Tech, LLC | $302.27 | 2025 | Twiist |
| Medtronic Minimed, INC. | $287.80 | 2019-2020 | |
| Amgen INC. | $279.52 | 2019-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $246.59 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $230.16 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $224.79 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $188.58 | 2019-2025 | |
| Medtronic, INC. | $185.60 | 2021-2025 | Minimed 780g, Vanta Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $167.52 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $147.97 | 2023-2025 | Isturisa, Signifor Lar |
| Radius Health, INC. | $132.13 | 2019-2025 | Tymlos |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Mcgregor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.